Full-Time

Finance Analyst

Essbase

Posted on 4/21/2025

Agilent Technologies

Agilent Technologies

10,001+ employees

eProcurement services for streamlined purchasing

No salary listed

Expert

Company Does Not Provide H1B Sponsorship

Bawal, India

This job includes the option to work remotely.

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Required Skills
SAP Products
Excel/Numbers/Sheets
Requirements
  • Finance graduate/postgraduate with 10+ years of experience in Hyperion Essbase Systems (Proficient level)
  • Experience with full cycle implementation of Essbase, user-training, end-user support
  • Experience of owning Essbase cubes, snapshots and SmartView 21c
  • Proficiency with MS Excel is must and functional knowledge of systems like SAP, HANA will be an added advantage
  • Knowledge of DRM is a plus
  • Strong interpersonal skills including written, oral and presentation
  • Strong team player, analytical skills and ability to work independently with business acumen
  • Strong customer-focus and results orientation
Responsibilities
  • Working extensively on Hyperion-Essbase related activities across the companies
  • Serving as primary liaison with stockholders from an IT and Finance standpoint
  • Project lead proficiency including current state analysis, architect a solution, system upgrades, migrations, business assessments, and documents validations
  • Parameterized, standardized, and ad-hoc financial reporting
  • Implementation of redesigned reporting and planning processes
  • Change management and training of users on a successful deployment of the new process and systems
  • Complete System development life-cycle implementations, developing and clarifying organizational requirements, translating requirements into data and process designs
Desired Qualifications
  • Knowledge of DRM is a plus

Agilent Technologies provides electronic procurement services that help businesses streamline their purchasing processes. Their suite of eProcurement services allows clients to integrate their pricing into existing platforms, access a hosted catalog, and conduct transactions without paper. This system is designed to help businesses quickly find and purchase the products they need at the right price, enhancing productivity through automation and simplified workflows. Agilent stands out from competitors by focusing on reliability and quality, serving a diverse range of clients who benefit from their expertise. The company's goal is to lower costs and increase profitability for its clients by improving efficiency in procurement.

Company Size

10,001+

Company Stage

IPO

Headquarters

Santa Clara, California

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisitions like Sigsense enhance Agilent's AI capabilities in lab operations.
  • The trend towards paperless transactions boosts Agilent's service efficiency and appeal.
  • Automation in procurement is expected to increase, benefiting Agilent's offerings.

What critics are saying

  • Integration challenges from acquiring BIOVECTRA may disrupt Agilent's operations.
  • Multiple acquisitions could stretch Agilent's resources and management focus.
  • Increased competition from funded companies like RareCyte and Elegen may challenge Agilent.

What makes Agilent Technologies unique

  • Agilent offers a comprehensive suite of eProcurement services for streamlined purchasing.
  • The company focuses on automation and paperless transactions to enhance business productivity.
  • Agilent's hosted catalog and pricing integration simplify procurement processes for clients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Performance Bonus

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

6%

2 year growth

5%
Business Wire
Jul 30th, 2024
Agilent Acquires Sigsense, Creator of AI-Enabled Lab Operations Technology

Agilent has acquired Sigsense Technologies, a startup that uses artificial intelligence and power monitoring to optimize lab operations.

Biovectra
Jul 22nd, 2024
Agilent Technologies to Acquire BIOVECTRA Inc., Creating New Synergistic Opportunities to Improve Patient Care | BIOVECTRA

CHARLOTTETOWN, Prince Edward Island and SANTA CLARA, California – July 22, 2024 BIOVECTRA Inc. and Agilent Technologies, Inc. (NYSE: A) today announced the signing of an agreement for Agilent to acquire BIOVECTRA, a Canadian-based Contract Development and Manufacturing Organization, from H.I.G. Capital for $925 million. The acquisition provides the ability to expand the range of [...]Read More...

Finsmes
Jun 27th, 2024
RareCyte Secures $20M Financing

RareCyte, a Seattle, WA-based Life Sciences company providing precision biology platforms including instruments, reagents, software, and services, raised $20M in funding

Business Wire
May 14th, 2024
Elegen Raises $35 Million In Series B To Accelerate Expansion Into Clinical Manufacturing

SAN CARLOS, Calif.--(BUSINESS WIRE)--Elegen, the leader in next-generation DNA synthesis and production, today announced a Series B financing of $35 million led by Triatomic Capital. Also joining the round are strategic investors GSK, which recently entered a collaboration and licensing agreement with Elegen to use their proprietary cell-free DNA manufacturing technology in developing GSK’s vaccines and medicines, and John Ballantyne, co-founder of Aldevron. Elegen’s current investors, including Andreessen Horowitz (a16z Bio + Health), KdT Ventures, 8VC, Digitalis Ventures, ACVC Partners, Alix Ventures, AME Cloud Ventures and Agilent Technologies, also participated. The new funds will accelerate the extension of the company’s rapidly growing ENFINIA™ DNA product line across clinical workflows providing turnkey production of GMP-compliant DNA for clinical development of genetic medicines. “The age of genetic medicines is here, but these powerful modalities require innovative new manufacturing approaches to supply the critical input DNA material for rapid discovery, development and then wide-scale production,” said Matthew Hill, Ph.D., Elegen Founder and CEO. “With this investment, we will continue to push the boundaries of DNA synthesis to accelerate upstream discovery and enable rapid and streamlined deployment of new clinical modalities.”

GenomeWeb
Apr 3rd, 2024
Biofidelity Raises $24M to Expand US Commercialization of Lung Cancer Test, Product Pipeline

The firm said it also plans to use the money, which brings its total raised to $60 million, to establish a dedicated manufacturing facility in the UK.

INACTIVE